In the six centers participating in this study, both ADAMTS13 activity and inhibitors were measured in 36 out of 38 patients (94.7%), representing an acceptable diffusion and utilization in Italian clinical laboratories of this test that facilitates the differential diagnosis of TTP compared with other forms of thrombotic microangiopathies. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.